Vaxxinity & UCF to Collaborate on Space Medicine Research
In This Article:
By Karen E. Roman
Vaxxinity, Inc. (NASDAQ: VAXX) said it will collaborate with the University of Central Florida in the advancement of space medicine research through a grant funded by the state of Florida.
The goal is to further develop the company’s active immunotherapies to prevent and mitigate muscle and bone wasting, frequent in long-term spaceflights and which is also present in common age-related diseases, Vaxxinity said.
“The support for this research from the State of Florida exemplifies a commitment to pioneering solutions in the fields of space travel, as well as longevity and age-related diseases,” said Lou Reese, Vaxxinity’s Executive Chairman.
Contact: